Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term OCT changes in RRMS patients treated with Gilenya (fingolimod)
2012-000674-31Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fingolimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Novartis. Primary endpoint: Change in average RNFL thickness from baseline to 36 months. Started Apr 2012; status: completed.
02
Drugs
fingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2012-000674-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000674-31.